IBI-20089, a drug candidate for the treatment of cystoid macular oedema (CME), has completed patient enrollment for initial clinical testing, according to the drug's manufacturer, Icon Bioscience Inc (IBI).
Industry preview: Eye care companies announce presentations ahead of ASRS meeting
Companies in the retina space announced presentations ahead of the American Society of Retina Specialists meeting, to be held 17-20 July
PHOTON Results and Their Relation to DME Patients in Your Practice
John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.
Impact report highlights outcomes of Moorfields Eye Charity programmes
The organisation has secured £72.75 million for its new eye health centre
PULSAR Results and Their Relation to nAMD Patients in Your Practice
John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.
Semaglutide may be associated with non-arteritic ischemic optic neuropathy (NAION)
GLP-1 receptor agonists, such as Wegovy, Ozempic and Novo Nordisk, are becoming more prolific
Beacon Therapeutics announces new board members, funding to support XLRP and AMD programmes
The company has secured $170 million (approximately €157 million) in Series B funding